Cadonilimab plus chemotherapy ± bevacizumab as 1L treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): a randomized, double-blind, placebo-controlled phase 3 study (Compassion-16)
机构：[1]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[2]Fujian Med Univ, Clin Oncol Sch, Fujian Canc Hosp, Fuzhou, Peoples R China[3]Yunnan Canc Hosp, Kunming, Peoples R China[4]Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China[5]Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China[6]Zhejiang Canc Hosp, Hangzhou, Peoples R China浙江省肿瘤医院[7]Southwest Med Univ, Affiliated Hosp, Luzhou, Peoples R China[8]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China[9]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China河北医科大学第四医院[10]Changde First Peoples Hosp, Changde, Peoples R China[11]Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China[12]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China[13]Tongji Med Coll, Union Hosp, Wuhan, Peoples R China华中科技大学同济医学院附属协和医院[14]Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China南方医科大学珠江医院[15]Shandong First Med Univ, Canc Hosp, Jinan, Peoples R China[16]Chongqing Univ, Affiliated Canc Hosp, Chongqing, Peoples R China[17]Jiangxi Maternal & Child Hlth Hosp, Nanchang, Peoples R China[18]Gansu Prov Hosp, Lanzhou, Peoples R China[19]Akeso Biopharm Inc, Zhongshan, Peoples R China
第一作者机构：[1]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Wu Xiaohua,Sun Yang,Yang Hongying,et al.Cadonilimab plus chemotherapy ± bevacizumab as 1L treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): a randomized, double-blind, placebo-controlled phase 3 study (Compassion-16)[J].INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER.2024,34(SUPPL_3):A1-A2.doi:10.1136/ijgc-2024-IGCS.2.
APA：
Wu, Xiaohua,Sun, Yang,Yang, Hongying,Wang, Jing,Lou, Hanmei...&Xia, Michelle.(2024).Cadonilimab plus chemotherapy ± bevacizumab as 1L treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): a randomized, double-blind, placebo-controlled phase 3 study (Compassion-16).INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,34,(SUPPL_3)
MLA：
Wu, Xiaohua,et al."Cadonilimab plus chemotherapy ± bevacizumab as 1L treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): a randomized, double-blind, placebo-controlled phase 3 study (Compassion-16)".INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 34..SUPPL_3(2024):A1-A2
